ARKG

nemodigital

Did you try and follow Cathy Woods ARKG fund with this stock?

Mightylibra

I regret buying LEAP and ARKG without proper due diligence; I just bought into the delusional Cathie Wood at her peak.

ihopethisworksfornow

ARKG green, apple fading = Pump is fake

vinkulafu

Now why did you have to mention her name just when I’m just starting to forget how heavy my ARKG bags are?

ihopethisworksfornow

Like let’s take a quick overview here: Apple is dumping Google is red Amazon is red Nvidia is red MSFT is flat ARKG is pumping Crypto is pumping Quantum is pumping Ape trash is pumping. Does this seem *bullish* to you?

ihopethisworksfornow

https://www.reddit.com/r/wallstreetbets/s/MyKgkqhkwA Lmfao It’s really easy guys. The market generally follows Apple. ARKG is dogshit, so if it’s pumping the pump is fake. It’s like you guys don’t even study the market come on

ihopethisworksfornow

ARKG up almost 4% Pump is fake

Frogblaster77

It's been 5 years. ARKG was at ~$100 then, and sits at $28.16 right now.

civisterrae

Thank you for the advice btw, I'll make sure to post it the state of my portfolio next year for you :) I'm thinking of making a few more additions as I get some cash - especially PAVE, GRID, QTUM and ARKG.

dvdmovie1

I like investing in biotech, have never invested in EDIT (or CRSP, NTLA are other ARKG-ish names that have often come up.) "biotech winter" There's a lot of things that have done well. XBI actually had a good year last year. " if literally anything goes right (data, partnership, asset sale, etc) the stock could reprice hard." True, but at $2, you have to take into account that a lot EDIT-specific has not gone right, it isn't just the sector. This isn't down 97% since late 2021 because of factors beyond the company.

SantaFeCastle

I would hold onto ARKG if you haven't sold already. Gene editing is revolutionary and she has all the main companies in there. You bought it at the top of its hype, but that hype is going to become reality in a few years.

DownTown_44

Why is ARKG doing so well? Is Ark making a comeback?

dvdmovie1

IMO, RXRX is a very Cathie Wood stock. It conceptually sounds appealing/exciting theme but when you look at ARKG over the last 5 years, you can see the "hype years" and you can see the years where healthcare is struggling and fundamentals matter. In the latter (2021, 2022, 2024) , the fund has been at the bottom of the category. When you look at the long-term? 3YR/5YR/10YR the fund is at or near the bottom of the category. IMO, if you have one of the greatest growth investing periods that I've ever invested in and the 5 year chart is just a continual erosion, there's something amatter. Recursion merged with peer Exscientia in August 2024. If this was such a compelling area, why would that company sell itself way off the highs? The merger hasn't seemed to help RXRX either. In terms of trials: REC-994 (Cerebral Cavernous Malformation): Recursion's lead candidate failed to demonstrate convincing efficacy in Phase 2. While it met the primary goal of safety, long-term extension data showed no promising trends in MRI or functional outcomes, becoming indistinguishable from natural history. REC-2282 (Neurofibromatosis Type 2): Development was halted after preliminary Phase 2/3 data from the POPLAR-NF2 trial showed limited tumor shrinkage and clinical activity. While the 40mg dose passed a futility threshold, the totality of the data did not justify further investment. REC-3964 (C. difficile Infection): Despite being the first new chemical entity developed through the "RecursionOS" platform, this Phase 2 program was discontinued in May 2025. The company cited a strategic decision to focus on other areas rather than clinical setbacks. REC-4881 (Solid Tumors): A pause was announced for this drug specifically targeting solid tumors, though it remains in development for other indications like FAP (Familial Adenomatous Polyposis) where it has shown more positive results. The company has been around for a bit now and when you look at the pipeline, there is one thing in phase 2, nothing in phase 3, the rest are all phase 1/pre clinical. Looking at a discussion on r/biotech: "Think it came up in another thread, but they just don't give the vibe they know what they're doing in clinical development. It's hard to say it exactly. But somehow they don't talk like they understand how hard it is to actually get something to market and what needs to be done to make that happen." (https://www.reddit.com/r/biotech/comments/1f8icsi/with_few_specifics_recursion_underwhelms_with/ - another thread: https://www.reddit.com/r/biotech/comments/1klmsi1/what_do_you_guys_think_of_recursion/) Also, I wasn't even aware the CEO stepped down a couple mo ago. Again, not saying this is a zero and don't want to be harsh but I just think this is one of those things where the results haven't matched the hype. The stock is 33% short (which says something) so any good news and could get a short squeeze. There is some cash to get through the year and there is a pipeline, but nothing in that pipeline is in stage 3/is seeming to generate that much excitement. IMO, AI around genetic testing (TEM, GH, former ILMN spin off/source of controversy GRAL, NTRA) has been an investment theme that has delivered a lot more than AI drug discovery - at least at this point.

Extension-Look-9186

The leading ARKG holding is Tempus. Do the research and you will appreciate the strategy of marry clinical data with ultra high sensitivity testing using single cell sequencing and multiomics. In fact much of the ARKG portfolio is centered around transforming medical care, drug discovery, and leading edge biotechnology with an eye toward personalized medicine. The consequence of what the companies in the portfrolio are doing will drastically lower health care costs at the same time. Do the research, it will convince you. Then you can amke up your mind to hold or sell with a much more informed perspective.

Fenderstratguy

>So everyone’s been talking about how “you can’t beat the S&P or the Nasdaq.” You forgot an important qualifier - OVER LONG PERIODS OF TIME, IT IS VERY DIFFICULT TO BEAT THE MARKET (S&P500 is the proxy for the market). Actively managed funds beat the S&P500 about 50% of the time over a 1 year period. However, over 5 years 86% underperform the market. Over 10 years 91% underperform. And over 20 years over 94% underperform. To get the most up to date statistics, look up the SPIVA report below. I got suckered by Cathie Wood's ARKG (genomic) fund in 2021 when it was around $100/share - sold soon after and then saw it lose 90% of it's value the following year. - **SPIVA Report (S&P Index Vs Active) by S&P Global** – compares index fund vs active fund performance https://www.spglobal.com/spdji/en/spiva/article/spiva-us **Click the PDF icon to “DOWNLOAD FULL ARTICLE” and find report 1a for the stats.**

redditerman414

Figma, ARKG

Minute_Tune_6461

I think ARKG is pretty good. A better biotech would be XBI. I’m invested in both. Give it time.

RunningJay

ARKG. Should never have trusted that shill.

chemdude1414

No she didn’t, it just dropped out of the top 10 holdings in ARKG. ARK still maintains ~ 12% ownership of PacBio (largest of any single group). But ARK did drop from 36 million shares to 30 million in the most recent SEC filing. Probably wanted some gains from its peak at $2.40.

Coffeefairee

ARKG my only green friend today

TestingLifeThrow1z

For me I used to hold hundreds of shares of PLTR from IPO and sold them at 100% profit gain. I think about that hold all the time. I did my DD and I failed to hold, and really could have lifted my portfolio. At the same time I’ve still held stocks and ETFs like ARKG and XYZ, who aren’t even close to being in profit. I used a heat map and finviz screener to just see all the companies as blocks, see the sector, and see what’s going to do well. I want to get back to long term stock holding, so I’ll keep doing more DD for more plays, but it’s good to hear these holds are reputable. Are these a good buy now for me to add on to them?

Fox2_Fox2

I have heard of it as it was hyped a few years ago because Cathy Wood bought into it , I think, but I never bought it. She just bought PACB which I think does similar things. Some people are buying it because she did. I lost my ass on ARKK and ARKG a few years ago, so I am not following her anymore.

dvdmovie1

" but that its Cash App business benefits " True, but there's not much of a moat to that. In a year where the S and P is up 17.5%, XYZ is down 10% and PYPL is down 18%. IMHO, there are years where if a growth story isn't doing well then the primary consideration should be what's wrong with it/"maybe this isn't the growth story I thought it was/was advertised to be." This is one of those years. For all the discussion of Cash App and Venmo, PYPL is down 62% over the last 5 years and XYZ -50%. Cathie is up 56% YTD and yet still is negative over the last 5 years. She held all the "hot in 2020" things way too long and the Ark funds eventually took more than $22B in realized losses, including 1.5B on TDOC. If you look at ARKG, you literally see a fund that does very well during times of hype (2020) and is a disaster when fundamentals matter (worst in the category 2021/2022/2024.) If you had a stretch of years where hype was in short supply and people had to rely on fundamentals, I could see one or more Ark funds eventually close.

Mr_UBC_Geek

This stuff only works out great for short term bull markets. ARTY would be in the red if you brought at the peak of early 2021. ARKK would be red over 5 years and I'm red on my 5 year ARKG hold. XLK is great, SMH is good for exposure but VONG isn't giving the growth you'd want with the mega caps dominating. Future can't be determined, but most would do VOO over VONG.

RayU_AZ

The simple sucessful ETF portfolio I had used in the past is below. It's over- weight in tech, but thats where the returns have been the last couple of years. You can add other EFTs for other sectors to target, Xbi-biotech. I use the VOO/VEA combination before for non-US stocks and emerging markets. I like having a Cathy Wood's active managed ARK fund to boost returns, ARKK, ARKG or others. 1. VONG 80% 2. SOXX or SMH 5% 3. XLK %5 4. ARTY 5% 5. ARKK 5% I like VONG, 1000 Large cap growth over the plain VOO, S&P-500. I'm retired now with more time on my hands and have migrated over from hold & forget ETFs to pure stocks. Good luck.

TestingLifeThrow1z

Because everyone thinks they can win in a bull market. Ask this question in 2022 or a bear market, and there answer will change. Can’t blame them, even my Cathie Wood ARKG fund is up 40%+ in the last 6 months…

NeedsProcessControl

meanwhile, ARKG is up 9% on the day... Is this finally the transition back into those shit biotech names?

nifai

Don't worry fam, I got you. [Cathie Wood’s ARK buys Genedx, sells Quantum-Si stock By Investing.com](https://www.investing.com/news/company-news/cathie-woods-ark-buys-genedx-sells-quantumsi-stock-93CH-4293584) Cathie just sold 2 days ago! ARK’s ARKG ETF parted with a total of 498,068 shares of Quantum-Si Inc (NASDAQ:QSI), equating to $1,309,918. This sale represents the largest divestment by dollar value for the day and suggests a strategic shift away from the semiconductor company.

OutOfBananaException

What are you doing purchasing calls on zombie companies like PTON? Why isn't ZM and ARKG in there too, just to round it out a little?

ObviousDoxx

Saying this and then buying random emerging tech stocks (ARKK, ARKG, ARKQ type of stuff) is interesting.

InvisibleBlueUnicorn

why not ARKG to bet on the sector, but diversify risk ?

CategoryOnly2022

Cathie wood need to be voted out as ARKG ceo

F0rtysxity

Don't sell. Tomorrow when the opening bell rings I'm going to drop 3% of my portfolio into ARKG. I'm looking to spend less time looking at my portfolio and touch grass. I'm wildly optimistic. HOLD!

esr_productions

Does anyone know if tax loss harvesting can be applied against 401k withdrawal taxes? I made the same rookie mistake…ARKK & ARKG turned $50k into $23k for me.

steve_b

You can accumulate all your cap losses in a single year, use what you need and carry the rest forward. There's no point in holding onto a dead stock to "save" the losses for later. I had made a bunch off ARKG during the pandemic, but bought a smidge more during the high period OP mentions; my total cost basis was around $90, I think. After seeing it languish for years, I eventually dumped in in Jan 2024 for about a 70% loss, and bought up PBE instead, another genomics stock (since a genomics pure play was always what I was looking for anyway, not necessarily a Woods rocketship). Since then, ARKG has gone down another 20% and PBE has an ROI for me of about 5%. But I still get to carry forward all those losses from 2024 to use on my other gains.

YourMatt

Not OP, but I hold ARKG too. I think most of what she has said has been insane, and Tesla projections made me question her sanity. I believed in the genomic fund though, and I actually still do. I put in small amounts from time to time. If nothing else, I like that I’m supporting the viability of startups working in this space.

dvdmovie1

Holy shit I didn't realize that this was still so far off highs. Cathie is the lead manager of this and I don't think she has any healthcare background, so you get a fund that is basically any healthcare thing that is Ark-y and falls within various hype theme buckets. Whether that thing has any actual basis in working I don't know that Cathie is the best one to determine. She lost a billion and a half on Teladoc, and has held at least one healthcare company (Invitae) to zero (and I think there was another I'm forgetting.) It has not been a good year or two for healthcare, but when I look at a very aggressive healthcare mutual fund run by someone with a medical background and see it's down 10% in the last 5 years and ARKG is down 60% in the last 5 years, it does point to Cathie perhaps not being someone who should be running a healthcare fund. Ark really needed to find people with expertise to lead specialized funds.

Forward_Party_5355

I did that, and it stung, but I sold a long time ago. Sell and buy a Vanguard ETF. Trust me. Yeah, you'll take it as a loss at first, but you'll make your money back after a while, especially if you keep adding to the Vanguard ETF over time. What I found is that when it comes to ETF's, it's even more important to choose the right company that manages the ETF than it is to choose the right ETF that they offer. Even if the category of ARKG (Genomics) is fine and the companies in the ETF are fine, people still need to be buying ARKG. Let's say two years from now has a huge hype about genomics. Are people going to be running to ARK and Cathie Wood? Probably not. Their reputation was crushed during the Biden years. And I actually like Cathie Wood and Ark still. I believe in their ideas and still listen to their insights. I just don't like them enough to lose money on them. I take what I hear from them about their thoughts on growth sectors and put it in Vanguard.

ScottishBostonian

The ARKG fund is hot garbage, the others are not so bad. Biotech and pharma is not a good place for money right now (exec on medical side in big pharma)

athlaka916

Is there a threshold to where it’s not worth it to do this? Everything’s relative but say you spent $5k on ARKG or BB or something and you’re down 80%. Is it even worth it to take your $1k, eat the loss and buy a few shares of VTI?

curt_schilli

What is the equivalent dollar amount of ARKG you own? If you had that in cash, would you spend it on ARKG right now? If not, sell it and buy something else

FriendlyCaramel2945

Tell me where ARKG is in 5 years of holding..how long to hold to break even..still 70% down on ARKG here..

ValuableCoach4199

The worst at the bottom is not even showing. ARKG. -89%

Educational_Glass304

Selling some HIMS for a big gain and dropping a $1000 on my Cathie Wood ARKG fund for some capital losses still seems like a win. I'm still down about 70% on Cathie's fund and have a few thousand left to unload when I need to.

TestingLifeThrow1z

Regret most? ARKG. (good industry, bad asset management) Successful? I'd say the EV / Solar wave.

LargeSnorlax

Quick, tell ARKG, it forgot how

STONKLEAPS

Now 400k in ARKG leaps.

EfficientTorch

How's the ARKG?

IOFrame

> ARKG Close, but ASTS (aka the "meme" stock, per Elon Musk and most regards here until recently)

GreatAugret

Tell me you are long ARKG without telling me you are long ARKG

Warrlock608

I like the ARKG fund, I think crspr tech is the future and I like the idea of having exposure to a whole swath of companies vying for the space.

asscrackbanditz

ARKK ARKG Thanks Kathy

drunkimunki

Anyone else on $ARKG

Shanman150

I went with ARKG. Made a bunch of money in 2018, then chased that high for years afterwards until reluctantly selling sometime last year at a significant loss.

Ut_Prosim

As the pandemic started slowing and things reopening, I thought people would start doing things they missed (partying, traveling, etc.). I got a bunch of AWAY (airlines) and YOLO (cannabis). I also figured people would recognize the value of biotech given the enormous success of the vaccines, so I got a bunch of ARKG. All of them did terribly, losing 80% at best. I think one of the three is down 97%, LOL. I don't even pay attention to them since they're basically worthless, but maybe useful for tax losses one day.

speedstorm123

yeah, what I'm gonna do as a small gamble is basically just buy far OTM leaps (January 2027) on ARKG. If the industry picks up by then, or we have another one of those periodic genomic pumps, it's a nice 2-3x. If not, I'm down a couple hundred.

Forsaken_Pop_7951

Good point. In my opinion, if what you are looking for is exposure to the gene-editing space with a nice blend and having the fund work for you to ensure catching the upside, yes. Much better to have ARKG managing selecting stocks, balancing gene-editing portfolio, and let it grow. I would say that it also depends on the investor's strategy. I happen to have some tolerance and patience to wait it out, thus going after a few moonshots which while they carry a high risk am hoping for that high reward. Your point is definitely thought provoking to cast a wider net, safer risk management, low maintenance, and buy and hold long term.

speedstorm123

would it be better, instead, to go into ARKG? big reduction in r/R both ways

STONKLEAPS

AI bio super cycle is about to begin. 100K on ARKG leaps!

STONKLEAPS

Dude, the time is now to buy $TEM, but honestly, I have 100k in $ARKG leaps, which makes up 10+% of $TEM. AI Bios are way overlooked and will ramp up in the next month, IMO.

PSfreak10001

Yeah but this sub was also incredibly bullish on ARKK and ARKG

Xzlk

Just found a Robinhood port from 5 years ago. It has ARKK, ARKW, ARKG and ARKQ in it lmaoooo

Michikusa

I don’t know. This sub and others were gargling MSFTS balls years ago and look at it know. I thought I was smart and bought ARKK and ARKG instead. God I just cringed typing it out

gatovision

Is there a bigger pile of garbage ETF than ARKG?

Deep-Serve9260

Alright, I took Theta Stock Options Academy years ago through the crazy post-COVID market highs and that rough 2022 correction, so I feel like I gotta chime in on this review. It’s got some points, but it doesn’t quite match my experience, and I wanna add my 2 cents. Trying to learn options trading on your own? Man, it’s tough. There’s so many strategies—spreads, straddles, you name it—and then you’ve got all this complex stuff like Greeks, volatility, and expiration dates. It’s a lot to wrap your head around. Without a solid guide, you can easily screw it up and lose money. And for me i'd rather have a guide than figure it all out on m own. Their program lays it all out in one place, nice and clear, so you don’t have to piece it together from random YouTube videos or forums. It’s a real community too, not just a course, and for someone looking to get a grip on options, it’s honestly a great spot to start. Theta’s all about building wealth over the long haul, not chasing quick bucks. They hammer home stuff like picking great companies and steering clear of borrowing too much. Some folks think Theta’s supposed to hand you stock picks, but that’s not it—they show you what they’re doing and tell you to do your own homework. Pick stocks that fit your risk level, you know? A bunch of the stocks they talk about, like Microsoft, Apple, Visa, Nvidia, they’ve bounced back or even hit new highs, just like the S&P 500 climbing to 5300. Sure, some like ARKG or SE tanked, but that’s just how investing goes. You gotta diversify, can’t put all your eggs in one basket. The idea that Theta doesn’t teach risk management? Nah, that’s off. They go over how to tweak your trades, roll options, and keep your cash in check to avoid big losses. They’re real clear: don’t go wild with margin or loans, cause that’ll burn you when the market dips. If someone’s taking big hits, it’s usually cause they ignored that advice. The community on Facebook is pretty cool for swapping ideas, though it’s not always buzzing. The Theta team might take a bit to reply—group’s big, what do you expect?—but they’re focused on teaching you to stand on your own, not spoon-feeding answers. Those 140+ five-star Google reviews? They’re from real people, like me, who’ve seen good returns by sticking to the plan. If some reviews don’t show up, that’s probably Google’s algorithm messing around, not Theta’s fault. Look, investing carries risk, no way around it. Theta’s program and community has worked out great for me, getting me through the 2020 and 2022 dips without getting crushed. I’ve made better returns than I ever thought, cause I avoided borrowing, spread my investments, and followed their risk rules. If you’re looking to learn options without drowning in the complexity, Theta’s a fantastic place to get started. It’s not about guarantees—it’s about learning, staying disciplined, and making smart calls yourself.

Flipside68

XBI is down 55% since 2021 ARKG is down 80% Biotech needs a resurgence. I believe the reds will move on some health stuff soon after this Tarriff mess blows over. So might be a year or two out still

Warrlock608

By some miracle I timed the local bottom today. Had SQQQ and TSLQ, sold shortly after open, bought 30 shares of $85 Nvidia, 100 shares of TQQQ @ $37, some TSLR, ARKG, and 3 shares of SPY. Will track down my phone and post trades/positions, but long story short I felt like a fuckin genius this morning.

sonofalando

ARKG Any ticker related to automation id personally be bullish on. Not popular yet but next step if AI takes the leap automating away manual labor.

superregard

Where’s all my ARKG regards at? That post a while back predicting ARKG would be next made me yolo into a shitload of 01/16/26 $50 calls

pieandbiscuits1

ARKG... what was I thinking??

Hot-You-7366

ARKK is up 3.3% in 5 years. ARKW +66%. ARKG down -28%. SPY 97% QQQ 143% someone give me my own ETFs

spyapple

ARKG is good imho. Strong volume support at current price. Check it up

Warrlock608

Biotech stocks with CRSPR tech are picking up momentum. IMO throwing some money at ARKG for the long haul is a pretty solid play.

365thisyear

CRSP and ARKG make me rich

KarmaPolice6

Where’s the ARKG guy from the fall? Looks like it’s about to go bananas. AI + Biotech picking up steam.

coloradoinsuranceguy

Nice gain! Lots of good opportunities in the market right now that aren’t closely tied to US politics. I like Chinese tech and advanced manufacturing as well as gene-editing and cutting edge drug discovery companies like those listed in ARKG. Both sectors are coming out of deep, prolonged bear markets and could see major growth.

QuantumHQ

ARKK, ARKG and IVR, all speculative investments made in 2021. Sometimes that is how you learn.

365thisyear

ARKG gonna break 30?

365thisyear

CRSP ARKG BEAM… biotech stocks are so back today

365thisyear

Is ARKG back?

365thisyear

CRSP and ARKG holy hell

MayaIsSunshine

Invested my life savings (~30k at the time) into ARK ETF funds in 2020, most of it going to ARKG. By late 2021 my holdings were down 90%.  Arguably, now I am being even dumber since I'm holding most of my money in a regular savings account right now because I'm afraid of that happening again. 

where-did-all-the

I was in ARKG. Only lost a few thousand, thankfully.

TheManBL2020

Dumped £5k into ARKG at an ATH. S&P 500 all the way now.

ryanv09

Same, but with ARKG

Young-faithful

As an ex-bagholder of Cathie wood’s ARKG fund- its performance is terrible. I mean the technology behind CRISPR for instance is really exciting. But the fund can’t be a science experiment charity unless she agrees to call it that. Maybe she’s too early and it will pay out with breakthroughs. I just don’t think she has the biotech experience and track record to be trusted. I don’t doubt that the people involved are very smart. I mean, I hope for my own selfish health reasons that things work out for them.

365thisyear

ARKG gonna break out of its 6mo range ??

neonb-fly

I do not know anything about ARKG and it’s practices, or what it is, or how it reacts to the market or anything, but looking at its 1y chart it tends to go up before dropping to $24 then back up on a monthly basis. It seems like it wants to go up based on volume and buyers, but I wouldn’t blame you for going to short it when historically that is its exact pattern. But without more knowledge of earnings or shares or ARKG at all I’d say this is a gamble and could go either way

Few_Mood2956

Based on the images you provided, here’s a quick breakdown: 1. The user is looking at a put option on ARKG with a strike price of $26.50, expiring February 14. 2. The max profit is listed as $2,550, while the max loss is $100, which suggests a high-risk, high-reward setup. 3. ARKG’s current price is around $26.57, and after-hours, it’s showing a slight increase to $27.00. 4. The technical charts show: • A recent bounce from $22.27, indicating some support. • MACD and RSI showing mixed signals—momentum is trying to recover. • Volume patterns suggest some buying interest. 5. The short-term trend (daily and weekly charts) suggests ARKG is trying to stabilize or even rebound. Should He Short ARKG with This Option? • Pros: • If ARKG drops below $26.50, the option gains value. • The downside risk is limited to $100. • Volatility could create a sharp downward move. • Cons: • ARKG is showing some bullish momentum. • The expiration is very close (next week), meaning theta (time decay) will be high. • If ARKG stays above $26.50 or trends higher, the option will expire worthless. Conclusion: This trade is a pure gamble unless there’s a strong catalyst for a drop next week. Given the current technical indicators, ARKG does not look extremely bearish at the moment. If the goal is to bet on short-term downside, a tighter stop-loss strategy would be needed. A safer play might be waiting for more confirmation of downward movement before entering or picking an expiration further out to allow more time for the trade to work.

365thisyear

Is ARKG finally gonna break out??

365thisyear

ARKG 50 cents away from a generational breakout

365thisyear

ARKG ???

365thisyear

ARKG and CRSP today

365thisyear

ARKG gonna go green again

L3arrick

ARKG trading above high volume today.

HatGlove

ARKG has not been kind to me 

dvdmovie1

I'd sell the cruise stuff into strength. Yes, you've gotten varying degrees of bounce off the covid bottom but long-term it's not a great business and it's highly cyclical. "ARKG: 3.5K" No. Just no. "NIO: 33K" No. Too much in EVs and if you feel you need to own Chinese EV names for some reason I'd rather BYD.

Ankari

I just closed my $ARKG Jan 17 $29 calls for 270% gains. What's next on yh menu?

jeddwong

Man, this is regard-level ambitious, but I see almost all ARKG holdings going up after the post, and many of them are going up A LOT! This might work? Wow, I really want to see it heppen now!!!!! Godspeed, my brothers!

kerrykingzgo-T

ARKG  never again cunts!!